Clinical Evaluation of BRL29060A (paroxetine hydrochloride hydrate) in social phobia/social anxiety disorder - A double-blind, placebo-controlled study- phase III study.
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Paroxetine (Primary)
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Jul 2012 Additional trial location (France) identified as reported by ClinicalTrials.gov.
- 28 Jun 2007 Status changed from in progress
- 06 Nov 2006 New trial record.